Sanofi Pasteur is now accepting orders for Quadracel™ (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine). Doses are available in a 10-dose package, vial presentation (NDC# 49281-562-10; see full product information).
Orders can be placed now by going to http://www.VaccineShoppe.com and are expected to ship in February 2017.
The Sanofi Pasteur Fluzone® Partner pricing and terms for the upcoming 2017-2018 flu season have been announced and sent to our membership. If you are a CPP member and did not receive the details, please contact us.
The pre-book period is now open and you can make your flu reservation at any time by going to http://www.VaccineShoppe.com. Reservations must be confirmed by March 31, 2017.
If you have any questions or need additional information, please don’t hesitate to contact the CPP office at 614-722-2145 or your Sanofi Pasteur representative.
Sanofi Pasteur has announced several vaccine-related updates:
End-of-Year Promotion: Members will receive an additional 2% off doses of Pentacel, Daptacel, IPOL and Menactra ordered between now and December 19, 2016. Orders must be shipped by December 21, 2016. This 2% promotional discount is in addition to the CPP member discounted price, the 1% online ordering discount and the 2% prompt pay discount.
New Pricing: Price changes that become effective on 1/1/2017 were announced this week. Please contact CPP for the most up-to-date member pricing.
- Pentacel®(Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate [Tetanus Toxoid Conjugate] Vaccine) – All direct customers with a Pentacel vaccine allocation will now be able to purchase an additional 25% on their current product allocation. Customers will be able to order 3 months of Pentacel vaccine at their new updated allocation between November 14 and December 20.
- Single-Entity Vaccines – DAPTACEL®(Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed), ActHIB®(Haemophilus b Conjugate Vaccine [Tetanus Toxoid Conjugate]), and IPOL®(Poliovirus Vaccine Inactivated) – All direct customers will now be able to purchase product as needed.
- Tenivac® – Sanofi has experienced a manufacturing delay related to Tenivac production that will affect supply of this vaccine through the first part of 2017. They anticipate that the supply will improve in the 2nd half of 2017. In the meantime, Sanofi recommends considering the purchase of Tdap (Adacel) as an alternative for eligible patients.
If you have any questions or need additional information, please don’t hesitate to contact CPP at 614-722-2145 or your local Sanofi Pasteur representative.
We at CPP would like to extend a heartfelt thanks to all of our members and vendor partners that have made this year a banner year for CPP! It is only through collaboration with our partners and sharing information and resources among our members that we are able to maximize opportunities for in-office immunizations for all patients. Thank you for all you do to minimmize vaccine-preventable diseases in our communities!
On November 1, 2016, Pfizer announced new pricing (effective January 27, 2017) and payment terms (effective December 1, 2016) for their Prevnar 13 and Trumenba vaccines. For details and updated pricing sheets, CPP members can contact the CPP office at 614-722-2145 or email@example.com.
In addition, the Advisory Committee on Immunization Practices (ACIP) met in October and provided additional guidance on the updated dosing schedules for one serogroup B meningococcal vaccine, MenB-FHbp (Trumenba).
- For persons at increased risk for meningococcal disease and during serogroup B outbreaks, 3 doses of MenB-FHbp administered at 0, 1-2, and 6 months.
- When given to healthy adolescents not at increased risk for meningococcal disease, 2 doses of MenB-FHbp at 0 and 6 months.
If approved by the CDC Director, the recommendations will become official once published in MMWR.
The AAP has received some emails concerning a new policy that was implemented by some payers in relation to the Medically Unlikely Edit (MUE) for CPT code 90461. The per day MUE edit was changed to 5. As soon as AAP staff and the Committee on Coding and Nomenclature became aware of this, they worked with Correct Coding Solutions (CCS) to have this edit increased to a number that was more clinically appropriate. CCS (as the CMS contractor for the National Correct Coding Initiative) worked with CMS directly and they agreed the number should be increased.
Here is an excerpt from the letter from CCS:
CMS will increase the MUE value from five (5) to eight (8) for this code. The new MUE value for this code will appear in the MUE version scheduled for January 1, 2017 and will be retroactive to the implementation date of…July 1, 2016.
Some AAP members have reported issues with the UnitedHealthcare (UHC) Maximum Frequency policy limit for CPT code 90461. The AAP is currently working with UHC to resolve this and determine what their course of action will be in light of the change by CMS. If you have any other payers denying, please email the coding hotline firstname.lastname@example.org.
In October, the FDA approved a 2-dose vaccination regimen for Gardasil 9, for use in girls and boys 9 through 14 years of age. For adolescents, Gardasil 9 can be administered using the 3-dose (0, 2, 6 months) or the 2-dose schedule (0, 6-12 months). For patients 15 through 26 years of age, Gardasil 9 is administered using the 3-dose regimen. For more information about the FDA’s approval, click here.
Additionally, the Advisory Committee on Immunization Practices (ACIP) discussed this schedule modification at their October meeting. The ACIP approved the following recommendation for the human papillomavirus vaccine by majority vote:
– 2-dose schedule for boys and girls initiating HPV vaccination series at 9 to 14 years (0,6-12 months)
– 3-dose schedule for persons initiating HPV vaccination series at older ages
– 3-dose schedule for immunocompromised persons
If the committee’s recommendation is approved by the CDC Director, it will become official once published in MMWR. For more information about the ACIP recommendations, please click here.